Omeros Corporation (OMER) 10-Year Financial Performance & Capital Metrics

OMER • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutOmeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.Show more

Revenue $0
EBITDA -$168M -2.9%
Net Income -$157M -33.1%
EPS (Diluted) -2.70 -43.6%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -
ROIC -72.43% -119.0%
Debt/Equity -
Interest Coverage -6.86 +39.5%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 96 (top 4%)
✓Share count reduced 7.3% through buybacks

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM9.94%

EPS CAGR

10Y-

5Y-

3Y-

TTM12.55%

ROCE

10Y Avg-134.75%

5Y Avg-70.72%

3Y Avg-48.92%

Latest-64.79%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	2.01B	15.23	387.53	33.97%	29.28%	21.28%	2.2%	0.21
ARGXargenx SE	49.47B	799.33	62.55	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.74	54.83	15.54%	32.78%	12.61%	12.77%	0.65
GLPGGalapagos N.V.	2.25B	34.12	30.46	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.33B	85.23	20.15	6.24%	21.94%	7.11%	3.43%	0.02
ALMSAlumis Inc. Common Stock	2.86B	24.34	-2.34		-11.08%	-63.71%		0.12
ZBIOZenas BioPharma, Inc.	1.21B	22.56	-6	-90%	-12.66%	-96.68%		0.00
ORKAOruka Therapeutics, Inc.	1.55B	32.00	-6.41			-22.44%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	13.51M	41.62M	64.83M	29.87M	111.81M	0	0	0	0	0
Revenue Growth %	24.06%	2.08%	0.56%	-0.54%	2.74%	-1%	-	-	-	-
Cost of Goods Sold+	1.04M	1.41M	1.08M	512K	2.65M	1.62M	1.39M	0	0	0
COGS % of Revenue	0.08%	0.03%	0.02%	0.02%	0.02%	-	-	-	-	-
Gross Profit+	12.47M	40.2M	63.75M	29.36M	109.15M	-1.62M	-1.39M	0	0	0
Gross Margin %	0.92%	0.97%	0.98%	0.98%	0.98%	-	-	-	-	-
Gross Profit Growth %	1.48%	2.22%	0.59%	-0.54%	2.72%	-1.01%	0.14%	1%	-	-
Operating Expenses+	83.71M	94.48M	107.64M	141.58M	172.53M	155.3M	172.23M	163.39M	164.53M	169.26M
OpEx % of Revenue	6.2%	2.27%	1.66%	4.74%	1.54%	-	-	-	-	-
Selling, General & Admin	35.33M	43.78M	52.04M	51.72M	62.84M	47.69M	53.46M	50.67M	49.66M	49.73M
SG&A % of Revenue	2.62%	1.05%	0.8%	1.73%	0.56%	-	-	-	-	-
Research & Development	48.38M	50.7M	55.6M	89.86M	109.7M	107.61M	118.78M	112.72M	114.87M	119.52M
R&D % of Revenue	3.58%	1.22%	0.86%	3.01%	0.98%	-	-	-	-	-
Other Operating Expenses	0	945K	0	0	0	0	0	0	0	0
Operating Income+	-71.24M	-54.28M	-43.9M	-112.22M	-63.38M	-156.92M	-173.62M	-163.39M	-164.53M	-169.26M
Operating Margin %	-5.27%	-1.3%	-0.68%	-3.76%	-0.57%	-	-	-	-	-
Operating Income Growth %	-0.02%	0.24%	0.19%	-1.56%	0.44%	-1.48%	-0.11%	0.06%	-0.01%	-0.03%
EBITDA+	-71.03M	-53.98M	-43.34M	-111.26M	-61.59M	-155.3M	-172.23M	-162.44M	-163.61M	-168.31M
EBITDA Margin %	-5.26%	-1.3%	-0.67%	-3.73%	-0.55%	-	-	-	-	-
EBITDA Growth %	-0.02%	0.24%	0.2%	-1.57%	0.45%	-1.52%	-0.11%	0.06%	-0.01%	-0.03%
D&A (Non-Cash Add-back)	209K	300K	551K	962K	1.79M	1.62M	1.39M	952K	920K	950K
EBIT	-71.52M	-58.93M	-42.45M	-123.43M	-61.83M	-169.64M	-171.88M	-159.33M	-144.08M	-157.95M
Net Interest Income+	-3.57M	-7.82M	-11.03M	-16.25M	-22.66M	-26.1M	-19.65M	-18.64M	-14.5M	-13.37M
Interest Income	0	0	0	0	0	654K	17.93K	4.06M	0	11.3M
Interest Expense	3.57M	7.82M	11.03M	16.25M	22.66M	26.75M	19.67M	22.7M	14.5M	24.68M
Other Income/Expense	-3.86M	-12.47M	-9.59M	-27.46M	-21.1M	-39.47M	-17.93M	-18.64M	-10.39M	-13.37M
Pretax Income+	-75.1M	-66.75M	-53.48M	-139.69M	-84.49M	-196.39M	-191.55M	-182.03M	-174.92M	-182.63M
Pretax Margin %	-5.56%	-1.6%	-0.82%	-4.68%	-0.76%	-	-	-	-	-
Income Tax+	0	0	0	-12.93M	0	-23.26M	0	0	0	0
Effective Tax Rate %	1%	1%	1%	0.91%	1%	0.7%	0.58%	-0.26%	0.67%	0.86%
Net Income+	-75.1M	-66.75M	-53.48M	-126.76M	-84.49M	-138.06M	-111.41M	47.42M	-117.81M	-156.81M
Net Margin %	-5.56%	-1.6%	-0.82%	-4.24%	-0.76%	-	-	-	-	-
Net Income Growth %	-0.02%	0.11%	0.2%	-1.37%	0.33%	-0.63%	0.19%	1.43%	-3.48%	-0.33%
Net Income (Continuing)	-75.1M	-66.75M	-53.48M	-126.76M	-84.49M	-173.13M	-191.55M	-182.03M	-174.92M	-182.63M
Discontinued Operations	0	0	0	0	0	35.07M	80.13M	229.45M	57.11M	25.81M
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-2.00	-1.65	-1.17	-2.61	-2.16	-2.41	3.12	0.46	-1.88	-2.70
EPS Growth %	0.1%	0.17%	0.29%	-1.23%	0.17%	-0.12%	2.29%	-0.85%	-5.09%	-0.44%
EPS (Basic)	-2.00	-1.65	-1.17	-2.61	-2.16	-2.41	3.12	0.46	-1.88	-2.70
Diluted Shares Outstanding	37.56M	40.45M	45.54M	48.58M	49.52M	57.18M	62.34M	62.74M	62.74M	58.17M
Basic Shares Outstanding	37.56M	40.45M	45.54M	48.58M	49.52M	57.18M	62.34M	62.74M	62.74M	58.17M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	37.15M	60.26M	108.37M	89.87M	103.75M	151.28M	247.96M	443.24M	217.9M	134.12M
Cash & Short-Term Investments	28.26M	45.33M	83.75M	60.5M	60.79M	134.95M	157.27M	194.92M	171.85M	90.13M
Cash Only	1.36M	2.22M	3.39M	5.86M	3.08M	10.5M	100.81M	11.01M	7.11M	3.4M
Short-Term Investments	26.9M	43.11M	80.36M	54.64M	57.7M	124.45M	56.46M	183.91M	164.74M	86.73M
Accounts Receivable	6.52M	12.04M	17.14M	22.82M	35.19M	3.84M	82.47M	242.02M	6.72M	36.82M
Days Sales Outstanding	176.08	105.57	96.53	278.85	114.87	-	-	-	-	-
Inventory	472K	1.13M	443K	52.51M	1.15M	1.35M	0	0	0	0
Days Inventory Outstanding	165.49	291.59	150	37.43K	157.69	306.05	-	-	-	-
Other Current Assets	0	0	0	6.46M	6.63M	681K	67K	6.3M	30.75M	7.17M
Total Non-Current Assets+	11.85M	7.02M	7.96M	6.07M	33.22M	29.76M	171.31M	147.73M	160.37M	142.96M
Property, Plant & Equipment	951K	1.18M	2.12M	3.85M	30.91M	28.08M	30.01M	23.25M	20.58M	17.64M
Fixed Asset Turnover	14.21x	35.24x	30.56x	7.77x	3.62x	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	10.68M	5.83M	5.83M	1.15M	1.15M	0	0	0	0	0
Other Non-Current Assets	219K	0	0	1.07M	1.16M	1.68M	141.31M	124.48M	139.79M	125.32M
Total Assets+	48.99M	67.28M	116.33M	95.94M	136.97M	181.04M	419.27M	590.97M	378.27M	277.08M
Asset Turnover	0.28x	0.62x	0.56x	0.31x	0.82x	-	-	-	-	-
Asset Growth %	3.42%	0.37%	0.73%	-0.18%	0.43%	0.32%	1.32%	0.41%	-0.36%	-0.27%
Total Current Liabilities+	16.25M	16.07M	26.31M	37.36M	55.46M	36.74M	51.79M	136.38M	53.32M	79.53M
Accounts Payable	6.43M	2.52M	6.69M	6.28M	5.33M	4.2M	13.4M	5.99M	7.71M	5.91M
Days Payables Outstanding	2.25K	651.16	2.27K	4.48K	732.47	948.41	3.53K	-	-	-
Short-Term Debt	73K	198K	490K	889K	3.5M	0	0	94.38M	8.58M	21M
Deferred Revenue (Current)	0	-198K	-490K	-889K	0	0	0	0	0	0
Other Current Liabilities	2.52M	8.61M	16.46M	26.58M	43.08M	3.95M	3.71M	7.82M	0	29.51M
Current Ratio	2.29x	3.75x	4.12x	2.41x	1.87x	4.12x	4.79x	3.25x	4.09x	1.69x
Quick Ratio	2.26x	3.68x	4.10x	1.00x	1.85x	4.08x	4.79x	3.25x	4.09x	1.69x
Cash Conversion Cycle	-1.91K	-254	-2.02K	33.24K	-459.92	-	-	-	-	-
Total Non-Current Liabilities+	58.98M	88.65M	92.83M	-41.58M	190.53M	265.06M	343.7M	368.9M	349.94M	380.16M
Long-Term Debt	49.77M	79.51M	83.31M	148.98M	158.21M	236.29M	313.46M	220.91M	329.7M	166.58M
Capital Lease Obligations	206K	324K	810K	1.58M	32.32M	28.77M	29.13M	22.43M	18.14M	13.47M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	9M	8.82M	8.72M	8.18M	0	0	1.11M	125.57M	2.09M	200.11M
Total Liabilities	75.23M	104.72M	119.14M	-4.22M	245.99M	301.79M	395.49M	505.29M	403.25M	459.69M
Total Debt+	49.84M	79.71M	84.61M	151.45M	194.03M	268.84M	347.84M	342.02M	361.58M	207.02M
Net Debt	48.48M	77.49M	81.21M	145.59M	190.95M	258.34M	247.03M	331.01M	354.48M	203.62M
Debt / Equity	-	-	-	0.23x	-	-	14.63x	3.99x	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-19.94x	-6.94x	-3.98x	-6.91x	-2.80x	-5.87x	-8.83x	-7.20x	-11.35x	-6.86x
Total Equity+	-26.23M	-37.45M	-2.81M	650.13M	-109.02M	-120.75M	23.78M	85.68M	-24.98M	-182.61M
Equity Growth %	0.38%	-0.43%	0.92%	232.03%	-1.17%	-0.11%	1.2%	2.6%	-1.29%	-6.31%
Book Value per Share	-0.70	-0.93	-0.06	13.38	-2.20	-2.11	0.38	1.37	-0.40	-3.14
Total Shareholders' Equity	-26.23M	-37.45M	-2.81M	650.13M	-109.02M	-120.75M	23.78M	85.68M	-24.98M	-182.61M
Common Stock	380K	438K	482K	490K	542K	616K	626K	628K	611K	580K
Retained Earnings	-403.14M	-469.89M	-523.37M	650.13M	-734.61M	-872.67M	-683.13M	-635.72M	-753.53M	-910.35M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-2.43M	-2.73M	-3.28M	-4.25M	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-65.21M	-51.5M	-36.23M	-103.74M	-60.07M	-100.09M	-109.72M	-86.48M	74.73M	-148.8M
Operating CF Margin %	-4.83%	-1.24%	-0.56%	-3.47%	-0.54%	-	-	-	-	-
Operating CF Growth %	-0.12%	0.21%	0.3%	-1.86%	0.42%	-0.67%	-0.1%	0.21%	1.86%	-2.99%
Net Income	-75.1M	-66.75M	-53.48M	-126.76M	-84.49M	-138.06M	-191.55M	-182.03M	-117.81M	-156.81M
Depreciation & Amortization	209K	300K	551K	962K	1.79M	1.62M	1.39M	952K	920K	950K
Stock-Based Compensation	9.58M	13.58M	12.69M	11.71M	13.79M	14.93M	0	0	11.65M	10.49M
Deferred Taxes	1.31M	5.59M	0	-12.93M	0	-12.01M	0	0	0	0
Other Non-Cash Items	1.04M	1.98M	4.19M	18.98M	9.23M	25.86M	94.54M	213.56M	-67.45M	-33.17M
Working Capital Changes	-2.26M	-6.21M	-172K	4.29M	-394K	7.58M	-14.11M	-118.97M	247.42M	29.74M
Change in Receivables	-6.13M	-5.52M	-5.11M	-6.17M	-12.37M	31.34M	-34.31M	-175.07M	245.72M	40.01M
Change in Inventory	96K	-656K	685K	355K	-1.06M	-208K	0	0	0	0
Change in Payables	4.2M	-319K	9.52M	10.54M	13.28M	-19.74M	14.64M	-10.66M	0	0
Cash from Investing+	-20.61M	-16.34M	-37.6M	25.15M	-3.4M	-67.03M	193.71M	-127.56M	27.45M	82.22M
Capital Expenditures	-240K	-126K	-350K	-567K	-334K	-283K	-277K	-113K	-426K	-165K
CapEx % of Revenue	0.02%	0%	0.01%	0.02%	0%	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-240K	-126K	-37.25K	25.72K	-3.07K	0	0	0	0	0
Cash from Financing+	86.83M	68.7M	75M	81.05M	60.7M	174.53M	6.32M	124.25M	-106.08M	62.88M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-7.58M	6.5M	11.77M	-28.57M	7.6M	-17.34M	-241K	0	150K	116.07M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-65.45M	-51.63M	-36.58M	-104.3M	-60.41M	-100.37M	-110M	-86.6M	74.3M	-148.97M
FCF Margin %	-4.84%	-1.24%	-0.56%	-3.49%	-0.54%	-	-	-	-	-
FCF Growth %	-0.13%	0.21%	0.29%	-1.85%	0.42%	-0.66%	-0.1%	0.21%	1.86%	-3%
FCF per Share	-1.74	-1.28	-0.80	-2.15	-1.22	-1.76	-1.76	-1.38	1.18	-2.56
FCF Conversion (FCF/Net Income)	0.87x	0.77x	0.68x	0.82x	0.71x	0.72x	0.98x	-1.82x	-0.63x	0.95x
Interest Paid	0	0	0	0	0	11.6M	0	0	29.92M	35.69M
Taxes Paid	0	0	0	0	0	0	0	0	3.29M	165K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-39.16%	-31.23%	-	-468.52%	86.63%	-388.17%	-
Return on Invested Capital (ROIC)	-894.65%	-130.72%	-55.59%	-19.26%	-10.83%	-107.22%	-63.77%	-35.65%	-33.07%	-72.43%
Gross Margin	92.29%	96.61%	98.34%	98.29%	97.63%	-	-	-	-	-
Net Margin	-555.9%	-160.38%	-82.5%	-424.39%	-75.57%	-	-	-	-	-
Debt / Equity	-	-	-	0.23x	-	-	14.63x	3.99x	-	-
Interest Coverage	-19.94x	-6.94x	-3.98x	-6.91x	-2.80x	-5.87x	-8.83x	-7.20x	-11.35x	-6.86x
FCF Conversion	0.87x	0.77x	0.68x	0.82x	0.71x	0.72x	0.98x	-1.82x	-0.63x	0.95x
Revenue Growth	2406.31%	208.07%	55.77%	-53.93%	274.33%	-100%	-	-	-	-

Frequently Asked Questions

Growth & Financials

Omeros Corporation (OMER) grew revenue by 0.0% over the past year. Growth has been modest.

Omeros Corporation (OMER) reported a net loss of $121.2M for fiscal year 2024.

Dividend & Returns

Omeros Corporation (OMER) had negative free cash flow of $105.3M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Omeros Corporation (OMER) 10-Year Financial Performance & Capital Metrics

OMER • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

Revenue $0
EBITDA -$168M -2.9%
Net Income -$157M -33.1%
EPS (Diluted) -2.70 -43.6%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -
ROIC -72.43% -119.0%
Debt/Equity -
Interest Coverage -6.86 +39.5%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 96 (top 4%)
✓Share count reduced 7.3% through buybacks

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM9.94%

EPS CAGR

10Y-

5Y-

3Y-

TTM12.55%

ROCE

10Y Avg-134.75%

5Y Avg-70.72%

3Y Avg-48.92%

Latest-64.79%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	2.01B	15.23	387.53	33.97%	29.28%	21.28%	2.2%	0.21
ARGXargenx SE	49.47B	799.33	62.55	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.74	54.83	15.54%	32.78%	12.61%	12.77%	0.65
GLPGGalapagos N.V.	2.25B	34.12	30.46	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.33B	85.23	20.15	6.24%	21.94%	7.11%	3.43%	0.02
ALMSAlumis Inc. Common Stock	2.86B	24.34	-2.34		-11.08%	-63.71%		0.12
ZBIOZenas BioPharma, Inc.	1.21B	22.56	-6	-90%	-12.66%	-96.68%		0.00
ORKAOruka Therapeutics, Inc.	1.55B	32.00	-6.41			-22.44%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	13.51M	41.62M	64.83M	29.87M	111.81M	0	0	0	0	0
Revenue Growth %	24.06%	2.08%	0.56%	-0.54%	2.74%	-1%	-	-	-	-
Cost of Goods Sold+	1.04M	1.41M	1.08M	512K	2.65M	1.62M	1.39M	0	0	0
COGS % of Revenue	0.08%	0.03%	0.02%	0.02%	0.02%	-	-	-	-	-
Gross Profit+	12.47M	40.2M	63.75M	29.36M	109.15M	-1.62M	-1.39M	0	0	0
Gross Margin %	0.92%	0.97%	0.98%	0.98%	0.98%	-	-	-	-	-
Gross Profit Growth %	1.48%	2.22%	0.59%	-0.54%	2.72%	-1.01%	0.14%	1%	-	-
Operating Expenses+	83.71M	94.48M	107.64M	141.58M	172.53M	155.3M	172.23M	163.39M	164.53M	169.26M
OpEx % of Revenue	6.2%	2.27%	1.66%	4.74%	1.54%	-	-	-	-	-
Selling, General & Admin	35.33M	43.78M	52.04M	51.72M	62.84M	47.69M	53.46M	50.67M	49.66M	49.73M
SG&A % of Revenue	2.62%	1.05%	0.8%	1.73%	0.56%	-	-	-	-	-
Research & Development	48.38M	50.7M	55.6M	89.86M	109.7M	107.61M	118.78M	112.72M	114.87M	119.52M
R&D % of Revenue	3.58%	1.22%	0.86%	3.01%	0.98%	-	-	-	-	-
Other Operating Expenses	0	945K	0	0	0	0	0	0	0	0
Operating Income+	-71.24M	-54.28M	-43.9M	-112.22M	-63.38M	-156.92M	-173.62M	-163.39M	-164.53M	-169.26M
Operating Margin %	-5.27%	-1.3%	-0.68%	-3.76%	-0.57%	-	-	-	-	-
Operating Income Growth %	-0.02%	0.24%	0.19%	-1.56%	0.44%	-1.48%	-0.11%	0.06%	-0.01%	-0.03%
EBITDA+	-71.03M	-53.98M	-43.34M	-111.26M	-61.59M	-155.3M	-172.23M	-162.44M	-163.61M	-168.31M
EBITDA Margin %	-5.26%	-1.3%	-0.67%	-3.73%	-0.55%	-	-	-	-	-
EBITDA Growth %	-0.02%	0.24%	0.2%	-1.57%	0.45%	-1.52%	-0.11%	0.06%	-0.01%	-0.03%
D&A (Non-Cash Add-back)	209K	300K	551K	962K	1.79M	1.62M	1.39M	952K	920K	950K
EBIT	-71.52M	-58.93M	-42.45M	-123.43M	-61.83M	-169.64M	-171.88M	-159.33M	-144.08M	-157.95M
Net Interest Income+	-3.57M	-7.82M	-11.03M	-16.25M	-22.66M	-26.1M	-19.65M	-18.64M	-14.5M	-13.37M
Interest Income	0	0	0	0	0	654K	17.93K	4.06M	0	11.3M
Interest Expense	3.57M	7.82M	11.03M	16.25M	22.66M	26.75M	19.67M	22.7M	14.5M	24.68M
Other Income/Expense	-3.86M	-12.47M	-9.59M	-27.46M	-21.1M	-39.47M	-17.93M	-18.64M	-10.39M	-13.37M
Pretax Income+	-75.1M	-66.75M	-53.48M	-139.69M	-84.49M	-196.39M	-191.55M	-182.03M	-174.92M	-182.63M
Pretax Margin %	-5.56%	-1.6%	-0.82%	-4.68%	-0.76%	-	-	-	-	-
Income Tax+	0	0	0	-12.93M	0	-23.26M	0	0	0	0
Effective Tax Rate %	1%	1%	1%	0.91%	1%	0.7%	0.58%	-0.26%	0.67%	0.86%
Net Income+	-75.1M	-66.75M	-53.48M	-126.76M	-84.49M	-138.06M	-111.41M	47.42M	-117.81M	-156.81M
Net Margin %	-5.56%	-1.6%	-0.82%	-4.24%	-0.76%	-	-	-	-	-
Net Income Growth %	-0.02%	0.11%	0.2%	-1.37%	0.33%	-0.63%	0.19%	1.43%	-3.48%	-0.33%
Net Income (Continuing)	-75.1M	-66.75M	-53.48M	-126.76M	-84.49M	-173.13M	-191.55M	-182.03M	-174.92M	-182.63M
Discontinued Operations	0	0	0	0	0	35.07M	80.13M	229.45M	57.11M	25.81M
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-2.00	-1.65	-1.17	-2.61	-2.16	-2.41	3.12	0.46	-1.88	-2.70
EPS Growth %	0.1%	0.17%	0.29%	-1.23%	0.17%	-0.12%	2.29%	-0.85%	-5.09%	-0.44%
EPS (Basic)	-2.00	-1.65	-1.17	-2.61	-2.16	-2.41	3.12	0.46	-1.88	-2.70
Diluted Shares Outstanding	37.56M	40.45M	45.54M	48.58M	49.52M	57.18M	62.34M	62.74M	62.74M	58.17M
Basic Shares Outstanding	37.56M	40.45M	45.54M	48.58M	49.52M	57.18M	62.34M	62.74M	62.74M	58.17M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	37.15M	60.26M	108.37M	89.87M	103.75M	151.28M	247.96M	443.24M	217.9M	134.12M
Cash & Short-Term Investments	28.26M	45.33M	83.75M	60.5M	60.79M	134.95M	157.27M	194.92M	171.85M	90.13M
Cash Only	1.36M	2.22M	3.39M	5.86M	3.08M	10.5M	100.81M	11.01M	7.11M	3.4M
Short-Term Investments	26.9M	43.11M	80.36M	54.64M	57.7M	124.45M	56.46M	183.91M	164.74M	86.73M
Accounts Receivable	6.52M	12.04M	17.14M	22.82M	35.19M	3.84M	82.47M	242.02M	6.72M	36.82M
Days Sales Outstanding	176.08	105.57	96.53	278.85	114.87	-	-	-	-	-
Inventory	472K	1.13M	443K	52.51M	1.15M	1.35M	0	0	0	0
Days Inventory Outstanding	165.49	291.59	150	37.43K	157.69	306.05	-	-	-	-
Other Current Assets	0	0	0	6.46M	6.63M	681K	67K	6.3M	30.75M	7.17M
Total Non-Current Assets+	11.85M	7.02M	7.96M	6.07M	33.22M	29.76M	171.31M	147.73M	160.37M	142.96M
Property, Plant & Equipment	951K	1.18M	2.12M	3.85M	30.91M	28.08M	30.01M	23.25M	20.58M	17.64M
Fixed Asset Turnover	14.21x	35.24x	30.56x	7.77x	3.62x	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	10.68M	5.83M	5.83M	1.15M	1.15M	0	0	0	0	0
Other Non-Current Assets	219K	0	0	1.07M	1.16M	1.68M	141.31M	124.48M	139.79M	125.32M
Total Assets+	48.99M	67.28M	116.33M	95.94M	136.97M	181.04M	419.27M	590.97M	378.27M	277.08M
Asset Turnover	0.28x	0.62x	0.56x	0.31x	0.82x	-	-	-	-	-
Asset Growth %	3.42%	0.37%	0.73%	-0.18%	0.43%	0.32%	1.32%	0.41%	-0.36%	-0.27%
Total Current Liabilities+	16.25M	16.07M	26.31M	37.36M	55.46M	36.74M	51.79M	136.38M	53.32M	79.53M
Accounts Payable	6.43M	2.52M	6.69M	6.28M	5.33M	4.2M	13.4M	5.99M	7.71M	5.91M
Days Payables Outstanding	2.25K	651.16	2.27K	4.48K	732.47	948.41	3.53K	-	-	-
Short-Term Debt	73K	198K	490K	889K	3.5M	0	0	94.38M	8.58M	21M
Deferred Revenue (Current)	0	-198K	-490K	-889K	0	0	0	0	0	0
Other Current Liabilities	2.52M	8.61M	16.46M	26.58M	43.08M	3.95M	3.71M	7.82M	0	29.51M
Current Ratio	2.29x	3.75x	4.12x	2.41x	1.87x	4.12x	4.79x	3.25x	4.09x	1.69x
Quick Ratio	2.26x	3.68x	4.10x	1.00x	1.85x	4.08x	4.79x	3.25x	4.09x	1.69x
Cash Conversion Cycle	-1.91K	-254	-2.02K	33.24K	-459.92	-	-	-	-	-
Total Non-Current Liabilities+	58.98M	88.65M	92.83M	-41.58M	190.53M	265.06M	343.7M	368.9M	349.94M	380.16M
Long-Term Debt	49.77M	79.51M	83.31M	148.98M	158.21M	236.29M	313.46M	220.91M	329.7M	166.58M
Capital Lease Obligations	206K	324K	810K	1.58M	32.32M	28.77M	29.13M	22.43M	18.14M	13.47M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	9M	8.82M	8.72M	8.18M	0	0	1.11M	125.57M	2.09M	200.11M
Total Liabilities	75.23M	104.72M	119.14M	-4.22M	245.99M	301.79M	395.49M	505.29M	403.25M	459.69M
Total Debt+	49.84M	79.71M	84.61M	151.45M	194.03M	268.84M	347.84M	342.02M	361.58M	207.02M
Net Debt	48.48M	77.49M	81.21M	145.59M	190.95M	258.34M	247.03M	331.01M	354.48M	203.62M
Debt / Equity	-	-	-	0.23x	-	-	14.63x	3.99x	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-19.94x	-6.94x	-3.98x	-6.91x	-2.80x	-5.87x	-8.83x	-7.20x	-11.35x	-6.86x
Total Equity+	-26.23M	-37.45M	-2.81M	650.13M	-109.02M	-120.75M	23.78M	85.68M	-24.98M	-182.61M
Equity Growth %	0.38%	-0.43%	0.92%	232.03%	-1.17%	-0.11%	1.2%	2.6%	-1.29%	-6.31%
Book Value per Share	-0.70	-0.93	-0.06	13.38	-2.20	-2.11	0.38	1.37	-0.40	-3.14
Total Shareholders' Equity	-26.23M	-37.45M	-2.81M	650.13M	-109.02M	-120.75M	23.78M	85.68M	-24.98M	-182.61M
Common Stock	380K	438K	482K	490K	542K	616K	626K	628K	611K	580K
Retained Earnings	-403.14M	-469.89M	-523.37M	650.13M	-734.61M	-872.67M	-683.13M	-635.72M	-753.53M	-910.35M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-2.43M	-2.73M	-3.28M	-4.25M	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-65.21M	-51.5M	-36.23M	-103.74M	-60.07M	-100.09M	-109.72M	-86.48M	74.73M	-148.8M
Operating CF Margin %	-4.83%	-1.24%	-0.56%	-3.47%	-0.54%	-	-	-	-	-
Operating CF Growth %	-0.12%	0.21%	0.3%	-1.86%	0.42%	-0.67%	-0.1%	0.21%	1.86%	-2.99%
Net Income	-75.1M	-66.75M	-53.48M	-126.76M	-84.49M	-138.06M	-191.55M	-182.03M	-117.81M	-156.81M
Depreciation & Amortization	209K	300K	551K	962K	1.79M	1.62M	1.39M	952K	920K	950K
Stock-Based Compensation	9.58M	13.58M	12.69M	11.71M	13.79M	14.93M	0	0	11.65M	10.49M
Deferred Taxes	1.31M	5.59M	0	-12.93M	0	-12.01M	0	0	0	0
Other Non-Cash Items	1.04M	1.98M	4.19M	18.98M	9.23M	25.86M	94.54M	213.56M	-67.45M	-33.17M
Working Capital Changes	-2.26M	-6.21M	-172K	4.29M	-394K	7.58M	-14.11M	-118.97M	247.42M	29.74M
Change in Receivables	-6.13M	-5.52M	-5.11M	-6.17M	-12.37M	31.34M	-34.31M	-175.07M	245.72M	40.01M
Change in Inventory	96K	-656K	685K	355K	-1.06M	-208K	0	0	0	0
Change in Payables	4.2M	-319K	9.52M	10.54M	13.28M	-19.74M	14.64M	-10.66M	0	0
Cash from Investing+	-20.61M	-16.34M	-37.6M	25.15M	-3.4M	-67.03M	193.71M	-127.56M	27.45M	82.22M
Capital Expenditures	-240K	-126K	-350K	-567K	-334K	-283K	-277K	-113K	-426K	-165K
CapEx % of Revenue	0.02%	0%	0.01%	0.02%	0%	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-240K	-126K	-37.25K	25.72K	-3.07K	0	0	0	0	0
Cash from Financing+	86.83M	68.7M	75M	81.05M	60.7M	174.53M	6.32M	124.25M	-106.08M	62.88M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-7.58M	6.5M	11.77M	-28.57M	7.6M	-17.34M	-241K	0	150K	116.07M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-65.45M	-51.63M	-36.58M	-104.3M	-60.41M	-100.37M	-110M	-86.6M	74.3M	-148.97M
FCF Margin %	-4.84%	-1.24%	-0.56%	-3.49%	-0.54%	-	-	-	-	-
FCF Growth %	-0.13%	0.21%	0.29%	-1.85%	0.42%	-0.66%	-0.1%	0.21%	1.86%	-3%
FCF per Share	-1.74	-1.28	-0.80	-2.15	-1.22	-1.76	-1.76	-1.38	1.18	-2.56
FCF Conversion (FCF/Net Income)	0.87x	0.77x	0.68x	0.82x	0.71x	0.72x	0.98x	-1.82x	-0.63x	0.95x
Interest Paid	0	0	0	0	0	11.6M	0	0	29.92M	35.69M
Taxes Paid	0	0	0	0	0	0	0	0	3.29M	165K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-39.16%	-31.23%	-	-468.52%	86.63%	-388.17%	-
Return on Invested Capital (ROIC)	-894.65%	-130.72%	-55.59%	-19.26%	-10.83%	-107.22%	-63.77%	-35.65%	-33.07%	-72.43%
Gross Margin	92.29%	96.61%	98.34%	98.29%	97.63%	-	-	-	-	-
Net Margin	-555.9%	-160.38%	-82.5%	-424.39%	-75.57%	-	-	-	-	-
Debt / Equity	-	-	-	0.23x	-	-	14.63x	3.99x	-	-
Interest Coverage	-19.94x	-6.94x	-3.98x	-6.91x	-2.80x	-5.87x	-8.83x	-7.20x	-11.35x	-6.86x
FCF Conversion	0.87x	0.77x	0.68x	0.82x	0.71x	0.72x	0.98x	-1.82x	-0.63x	0.95x
Revenue Growth	2406.31%	208.07%	55.77%	-53.93%	274.33%	-100%	-	-	-	-

Frequently Asked Questions

Growth & Financials

Omeros Corporation (OMER) grew revenue by 0.0% over the past year. Growth has been modest.

Omeros Corporation (OMER) reported a net loss of $121.2M for fiscal year 2024.

Dividend & Returns

Omeros Corporation (OMER) had negative free cash flow of $105.3M in fiscal year 2024, likely due to heavy capital investments.